Search research articles
Contact Us
Filters
Showing results (441-450 of 471) with videos related to
Page
of 48
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 12, 2023
Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study
Reena Khanna, Christopher Ma, Malcolm Hogan, et al.
Gastroenterology
|
February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Geert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Alimentary Pharmacology & Therapeutics
|
July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Inflammatory Bowel Diseases
|
November 28, 2013
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States
Millie D Long, Susan Hutfless, Michael D Kappelman, et al.
Gastrointestinal Endoscopy
|
June 3, 2008
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial
Craig A Solem, Edward V Loftus, Joel G Fletcher, et al.
Gastroenterology
|
March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results
Julián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Gastroenterology
|
July 1, 2018
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries
Shailja C Shah, Hamed Khalili, Corinne Gower-Rousseau, et al.
Lancet (London, England)
|
June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G Feagan, Silvio Danese, Edward V Loftus, et al.
JAMA
|
July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Lancet (London, England)
|
June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert D'Haens, Remo Panaccione, Filip Baert, et al.
Page
of 48
Search research articles
Search
Showing results (441-450 of 471) with videos related to
Sort By:
Page
of 48
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 12, 2023
Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study
Reena Khanna, Christopher Ma, Malcolm Hogan, et al.
Gastroenterology
|
February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Geert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Alimentary Pharmacology & Therapeutics
|
July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Inflammatory Bowel Diseases
|
November 28, 2013
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States
Millie D Long, Susan Hutfless, Michael D Kappelman, et al.
Gastrointestinal Endoscopy
|
June 3, 2008
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial
Craig A Solem, Edward V Loftus, Joel G Fletcher, et al.
Gastroenterology
|
March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results
Julián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Gastroenterology
|
July 1, 2018
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries
Shailja C Shah, Hamed Khalili, Corinne Gower-Rousseau, et al.
Lancet (London, England)
|
June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G Feagan, Silvio Danese, Edward V Loftus, et al.
JAMA
|
July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Lancet (London, England)
|
June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert D'Haens, Remo Panaccione, Filip Baert, et al.
Page
of 48